October 15, 2025 07:00 AM EDT
Deals
Bioregnum

Which big phar­ma has the busiest BD team? You might be sur­prised

John Carroll

Editor & Founder

Biotech ex­ecs gen­er­al­ly point to need as the biggest dri­ver of deal­mak­ing. Some of the biggest play­ers — say Mer­ck and Bris­tol My­ers Squibb — are los­ing …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ake­so de­tails Chi­na da­ta for bis­pe­cif­ic in front­line lung can­cer, sets the stage for Sum­mit's glob­al tri­al

BioN­Tech stops fur­ther work on can­cer vac­cine in ad­vanced melanoma

Roche’s SERD is the first shown to work in non-mu­tant breast can­cer pa­tients

En­her­tu could move in­to 'cu­ra­tive' breast can­cer set­ting on the strength of Phase 3 da­ta

Ex­clu­sive: Sid Mukher­jee’s Faeth nets $25M for en­dome­tri­al can­cer study

sponsored

In sight: Ad­vanc­ing cell ther­a­py for reti­nal dis­ease

A service from the Financial Times